We are live on ! Find out more
KZR

Kezar Life Sciences

Delisted

KZR was delisted on the 8th of May, 2026.

77 hedge funds and large institutions have $123M invested in Kezar Life Sciences in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $109M → $123M (+$13.7M)

12% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 26

0.08% more ownership

Funds ownership: 5.01%5.09% (+0.08%)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

1% less funds holding

Funds holding: 7877 (-1)

93% less call options, than puts

Call options by funds: $5K | Put options by funds: $70K

Holders
77
Holders Change
-1
Holders Change %
-1.28%
% of All Funds
1.36%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
29
Reduced
26
Closed
10
Calls
$5K
Puts
$70K
Net Calls
-$65K
Net Calls Change
-$117K

KZR Hedge Fund Activity: Q4 2020 in Review

77 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2020, worth a combined $123M — up 13% from $109M a quarter earlier.

Fund positioning in KZR was balanced in Q4 2020: 10 funds opened new positions, 10 closed out, 29 added to existing stakes and 26 trimmed.

The largest buyer was Suvretta Capital Management, adding an estimated $4.75M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $4.51M sold.

  • 77 institutional investors held Kezar Life Sciences (KZR) as of Q4 2020, down from 78 in Q3 2020.
  • Funds reported $123M of Kezar Life Sciences stock for Q4 2020, up 13% quarter-over-quarter.
  • 10 funds opened new Kezar Life Sciences positions in Q4 2020 and 10 closed out, a net change of 0 holders.
  • The largest Kezar Life Sciences buyer in Q4 2020 was Suvretta Capital Management, an estimated $4.75M added.
  • The largest Kezar Life Sciences seller in Q4 2020 was Cormorant Asset Management, an estimated $4.51M sold.

Based on aggregated 13F filings for Q4 2020.